Drug manufacturer Lilly said this morning it looks forward to reviewing the Biden administration’s proposed new 340B administrative dispute resolution (ADR) regulation when it becomes available “and hope[s] that it addresses the serious shortcomings of the current rule.”
“As Lilly has been arguing for some time, and a federal court has now explicitly recognized, the 340B program is broken and can no longer be ‘implemented fairly for all concerned,’” a company spokesperson said. “The January 2021 340B Administrative Dispute Resolution (ADR) rule is one aspect of this program that must be fixed. In fact, a federal court agreed with Lilly that the ADR rule was promulgated unlawfully and issued a preliminary injunction against it.”
Drug manufacturer Lilly said this morning it looks forward to reviewing the Biden administration’s proposed new 340B administrative dispute resolution (ADR) regulation when it becomes available “and hope[s] that it addresses the serious shortcomings of the current rule.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
